Compile Data Set for Download or QSAR
maximum 50k data
Found 112 with Last Name = 'ninan' and Initial = 'n'
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50231280(1-(3-cyano-4-fluorophenyl)-6-[4-(3-dimethylaminome...)
Affinity DataKi:  1.40nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM12676(1-(3-Aminobenzisoxazol-5-yl)-3-trifluoromethyl-N-[...)
Affinity DataKi:  1.60nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM12676(1-(3-Aminobenzisoxazol-5-yl)-3-trifluoromethyl-N-[...)
Affinity DataKi:  1.60nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
TargetDipeptidyl peptidase 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical

LigandPNGBDBM11123((2S)-1-[(2S)-2-amino-3-[4-(2,4-difluorophenyl)phen...)
Affinity DataKi:  2.20nM ΔG°:  -49.4kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50231282(1-(3-aminobenzo[d]isoxazol-5-yl)-6-[4-(3-dimethyla...)
Affinity DataKi:  3nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDipeptidyl peptidase 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical

LigandPNGBDBM11121((2S)-1-[(2S)-2-amino-3-[4-(4-fluorophenyl)phenyl]p...)
Affinity DataKi:  3.10nM ΔG°:  -48.6kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50231275(1-(3-aminobenzo[d]isoxazol-5-yl)-7-fluoro-6-[2-flu...)
Affinity DataKi:  4.10nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50231284(1-(3-aminobenzo[d]isoxazol-5-yl)-6-[4-(2-dimethyla...)
Affinity DataKi:  4.40nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50231271(1-(3-aminobenzo[d]isoxazol-5-yl)-6-{4-[(2-dimethyl...)
Affinity DataKi:  4.90nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50231279(1-(3-aminobenzo[d]isoxazol-5-yl)-6-{4-[(3-dimethyl...)
Affinity DataKi:  5.20nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDipeptidyl peptidase 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical

LigandPNGBDBM11122((2S)-1-[(2S)-2-amino-3-[4-(2-fluorophenyl)phenyl]p...)
Affinity DataKi:  5.30nM ΔG°:  -47.2kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50231283(1-(3-aminobenzo[d]isoxazol-5-yl)-7-fluoro-6-[2-flu...)
Affinity DataKi:  6.40nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50231270(1-(3-aminobenzo[d]isoxazol-5-yl)-6-(2'-dimethylami...)
Affinity DataKi:  8.10nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50182163(4-[7-bromo-1-(2,5-difluoro-benzyl)-1H-benzoimidazo...)
Affinity DataKi:  10nMAssay Description:Inhibition of C1SMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDipeptidyl peptidase 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical

LigandPNGBDBM11118((2S)-1-[(2S)-2-amino-3-(4-phenylphenyl)propanoyl]p...)
Affinity DataKi:  13nM ΔG°:  -45.0kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50233679(CHEMBL399284 | N-[3'-(5-carbamimidoyl-2-methylsulf...)
Affinity DataKi:  14nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50231272(1-(3-amino-1,2-benzisoxazol-5-yl)-6-(4-{2-[(dimeth...)
Affinity DataKi:  15.9nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50233691(4-(2'-amino-6'-methyl-biphenyl-3-sulfonyl)-5-methy...)
Affinity DataKi:  20nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50182160(4-[7-bromo-1-(2,6-dichloro-benzyl)-1H-benzoimidazo...)
Affinity DataKi:  20nMAssay Description:Inhibition of C1SMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDipeptidyl peptidase 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical

LigandPNGBDBM11119((2S)-1-[(2S)-2-amino-3-[4-(4-methylphenyl)phenyl]p...)
Affinity DataKi:  20nM ΔG°:  -43.9kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50233674(6-{3-[3'-(5-carbamimidoyl-2-methylsulfanyl-thiophe...)
Affinity DataKi:  22nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50231269(1-{4-[1-(3-aminobenzo[d]isoxazol-5-yl)-7-fluoro-3-...)
Affinity DataKi:  22.9nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50231274(1-{4-[1-(3-aminobenzo[d]isoxazol-5-yl)-7-fluoro-3-...)
Affinity DataKi:  26nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDipeptidyl peptidase 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical

LigandPNGBDBM11120((2S)-1-[(2S)-2-amino-3-[4-(3,4-dimethoxyphenyl)phe...)
Affinity DataKi:  26nM ΔG°:  -43.3kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDipeptidyl peptidase 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical

LigandPNGBDBM11113(6-{[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl...)
Affinity DataKi:  27nM ΔG°:  -43.2kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50182170(4-[7-bromo-1-(2-fluoro-5-nitro-benzyl)-1H-benzoimi...)
Affinity DataKi:  30nMAssay Description:Inhibition of C1SMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50233686(4-(2'-methyl-biphenyl-3-sulfonyl)-5-methylsulfanyl...)
Affinity DataKi:  30nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50182171(4-(1-benzyl-7-bromo-1H-benzoimidazole-5-sulfonyl)-...)
Affinity DataKi:  30nMAssay Description:Inhibition of C1SMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDipeptidyl peptidase 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical

LigandPNGBDBM11116((2S)-1-[(2S)-2-amino-3-(4-iodophenyl)propanoyl]pyr...)
Affinity DataKi:  34nM ΔG°:  -42.6kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDipeptidyl peptidase 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical

LigandPNGBDBM11124((2S)-1-[(2S)-2-amino-3-[4-(furan-2-yl)phenyl]propa...)
Affinity DataKi:  36nM ΔG°:  -42.5kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50233688(4-(2'-chloro-biphenyl-3-sulfonyl)-5-methylsulfanyl...)
Affinity DataKi:  40nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50233692(4-[3-(6-methyl-pyridin-2-yl)-benzenesulfonyl]-5-me...)
Affinity DataKi:  40nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50182159(4-[7-bromo-1-(2,6-difluoro-benzyl)-1H-benzoimidazo...)
Affinity DataKi:  40nMAssay Description:Inhibition of C1SMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50233694(5-[3'-(5-carbamimidoyl-2-methylsulfanyl-thiophene-...)
Affinity DataKi:  42nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50233677(4-(2'-hydroxymethyl-6'-methyl-biphenyl-3-sulfonyl)...)
Affinity DataKi:  50nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50182176(4-[7-bromo-1-(3-methyl-but-2-enyl)-1H-benzoimidazo...)
Affinity DataKi:  50nMAssay Description:Inhibition of C1SMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDipeptidyl peptidase 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical

LigandPNGBDBM11115((2S)-1-[(2S)-2-amino-3-phenylpropanoyl]pyrrolidine...)
Affinity DataKi:  63nM ΔG°:  -41.1kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50233689(5-methylsulfanyl-4-(6'-methyl-2'-{3-[2-(2H-tetrazo...)
Affinity DataKi:  64nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50182185(4-(1-allyl-7-bromo-1H-benzoimidazole-5-sulfonyl)-5...)
Affinity DataKi:  70nMAssay Description:Inhibition of C1SMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDipeptidyl peptidase 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical

LigandPNGBDBM11136((2S)-2-amino-3-[4-(2,4-difluorophenyl)phenyl]-1-(1...)
Affinity DataKi:  96nM ΔG°:  -40.1kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50182183(4-[7-chloro-3-(2,6-difluoro-benzyl)-3H-benzoimidaz...)
Affinity DataKi:  100nMAssay Description:Inhibition of C1SMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50182173(4-[7-chloro-1-(2,6-difluoro-benzyl)-1H-benzoimidaz...)
Affinity DataKi:  100nMAssay Description:Inhibition of C1SMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50233680(4-(2'-hydroxymethyl-biphenyl-3-sulfonyl)-5-methyls...)
Affinity DataKi:  120nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50233693(CHEMBL252619 | N-[3'-(5-carbamimidoyl-2-methylsulf...)
Affinity DataKi:  120nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50231286(1-{4-[1-(3-aminomethylphenyl)-7-fluoro-3-methyl-1H...)
Affinity DataKi:  124nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50233681(5-methylsulfanyl-4-(2'-vinyl-biphenyl-3-sulfonyl)-...)
Affinity DataKi:  140nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50231268(1-(3-aminobenzo[d]isoxazol-5-yl)-6-[4-(4-dimethyla...)
Affinity DataKi:  147nMAssay Description:Inhibition of human factor 10aMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50233676(3'-(5-carbamimidoyl-2-methylsulfanyl-thiophene-3-s...)
Affinity DataKi:  150nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50233683(4-(3'-hydroxy-biphenyl-3-sulfonyl)-5-methylsulfany...)
Affinity DataKi:  150nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetDipeptidyl peptidase 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical

LigandPNGBDBM11134(4-{4-[(2S)-2-amino-3-oxo-3-(1,3-thiazolidin-3-yl)p...)
Affinity DataKi:  160nM ΔG°:  -38.8kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 112 total ) | Next | Last >>
Jump to: